View all news

    OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health CanadaApproved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

    10/15/2021
    Download(opens in new window)PDF 137 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com